Trial reportScientific reports2021
Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 72 citations in OpenAlex.
- Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults.PLoS neglected tropical diseases · 2024Trial
- Tuberculosis treatment and cytotoxic immune signatures: a longitudinal study.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- The Imperative of Data Transparency for Pursuing Scientific Truth about COVID-19 Vaccination and Excess Deaths.JMA journal · 2026Article
- Bacillus Calmette-Guérin as adjuvant platform enhances immunogenicity of conserved epitopes from structural proteins of SARS-CoV-2.Frontiers in immunology · 2026Article
- Occlusion body-incorporated SARS-CoV-2 S-RBD via cypovirus polyhedrin-derived peptide: a novel insect cell-expressed antigen for high-accuracy COVID-19 diagnosis, and humoral immune response and hybrid immunity evaluation.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Reduced Fc-mediated antibody responses after COVID-19 mRNA vaccination in a cohort of people living with HIV-1.Scientific reports · 2025Observational
- Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach.Vaccines · 2025Review
- Pre-Existing Anti-Inflammatory Immune Conditions Influence Early Antibody Avidity and Isotype Profile Following ComirnatyVaccines · 2025Article
- Transcriptomic and miRNA Signatures of ChAdOx1 nCoV-19 Vaccine Response Using Machine Learning.Life (Basel, Switzerland) · 2025Article
- Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein.Scientific reports · 2025Article
- Humoral immune response to COVID-19 vaccines in onchocerciasis-infected individuals: a field study from Ghana.Frontiers in immunology · 2025Article
- Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses.Human vaccines & immunotherapeutics · 2024Article
- An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines.Scientific reports · 2024Article
- Evaluation of antibody responses in healthy individuals receiving SARS-CoV-2 inactivated vaccines.Biosafety and health · 2024Article
- Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies.Biomedical journal · 2024Review
- B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity.Cellular & molecular immunology · 2024Review
- mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review.Clinical and experimental medicine · 2024Review
- RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques.Vaccines · 2023Article
- Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine.Vaccines · 2023Article
- Production of Recombinant Zika Virus Envelope Protein by Airlift Bioreactor as a New Subunit Vaccine Platform.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or indicates that predict disease outcome in SARS-CoV-2 infection remains undefined. This work aimed to assess the antibody levels, avidity, and subclasses of IgG to RBD protein, in symptomatic patients with severe and mild forms of COVID-19 in Brazil using an adapted in-house RBD-IgG ELISA. The RBD IgG-ELISA showed 100% of specificity and 94.3% of sensibility on detecting antibodies in the sera of hospitalized patients. Patients who presented severe COVID-19 had higher anti-RBD IgG levels compared to patients with mild disease. Additionally, most patients analyzed displayed low antibody avidity, with 64.4% of the samples of patients who recovered from the disease and 84.6% of those who died in this avidity range. Our data also reveals an increase of IgG1 and IgG3 levels since the 8th day after symptoms onset, while IgG4 levels maintained less detectable during the study period. Surprisingly, patients who died during 8-14 and 15-21 days also showed higher anti-RBD IgG4 levels in comparison with the recovered (P < 0.05), suggesting that some life-threatening patients can elicit IgG4 to RBD antibody response in the first weeks of symptoms onset. Our findings constitute the effort to clarify IgG antibodies' kinetics, avidity, and subclasses against SARS-CoV-2 RBD in symptomatic patients with COVID-19 in Brazil, highlighting the importance of IgG antibody avidity in association with IgG4 detection as tool laboratory in the follow-up of hospitalized patients with more significant potential for life-threatening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.